The current contract arrangements for the supply of imported immunoglobulin products commenced on 1 January 2021. Those arrangements included provisions for some additional products to be added as they became available. The National Blood Authority is now pleased to announce that a new imported intravenous immunoglobulin (IVIg) product, Kiovig 10% (Takeda), will be available to order from Lifeblood from 1 May 2023.
From January 1, access to Thrombopoietin Receptor Agonists (TPORAs) became much easier for patients living with Immune Thrombocytopenia (ITP).
During the November 2022 Pharmaceutical Advisory Committee (PBAC) meeting, Avatrombopag was tabled for chronic ITP Patients.
From 1 January 2023, the maximum cost of general prescriptions under the PBS will fall for the first time in the 75-year history of the Pharmaceutical Benefits Scheme (PBS). It’s important that patients understand the changes and how they will affect them.
Over the last 3-6 months, ITP Australia has been working behind the scenes to develop some important patient collateral and materials and add more information across ITPAustralia.org.au.
HAVE YOUR SAY: Submit your letter to us, and we will hand deliver them when we travel to Canberra on Monday 5th September 2022.
The PBAC recommends removing restrictions to make it easier for ALL ITP Patients to access TPORAs.
Missed the ITP Australia Virtual Patient Conference for 2022, or would like to revisit one or more of the presentations? View them here.
The PBAC recommends a change for all listings and brands of Rituximab to be added to the Unrestricted Benefits listings.
Leading ITP clinicians come together and deliver consensus guidelines for the treatment of (ITP) in adult patients.